Adverum Biotechnologies (ADVM) AI Stock Analysis

• Market Cap: $47.63M
• Dividend Yield: N/A
• Average Volume (3M): 289.38K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.01
• Revenue Growth: N/A
• EPS Growth: 37.54%
• Country: US
• Employees: 155
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -2.25
• Shares Outstanding: 20,890,734
• 10 Day Avg. Volume: 498,496
• 30 Day Avg. Volume: 289,380
• PEG Ratio: -0.08
• Price to Book (P/B): 0.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.48
• Enterprise Value/Market Cap: 2.01
• Enterprise Value/Revenue: -8.42
• Enterprise Value/Gross Profit: -8.35
• Enterprise Value/Ebitda: -0.24
• 1Y Price Target: $15.33
• Price Target Upside: 578.32% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 40 Neutral
• Price Target: $2.00 ▼(-11.50%Downside)

The most significant factor affecting Adverum Biotechnologies' stock score is its poor financial performance, with persistent losses and liquidity risks. Technical analysis points to bearish market sentiment, and the valuation is weak due to negative earnings. The corporate event involving subtenant defaults adds to the risk profile, further impacting the overall score.

Positive Factors

Clinical Trials and Efficacy

The positive view on lead asset ixo-vec, believed to be a best-in-class gene therapy candidate for wet age-related macular degeneration, remains unchanged.

Financial Stability

The $125.7M in cash and equivalents is anticipated to fund operations into the second half of 2025, supporting the ongoing pivotal program.

Patient Enrollment and Study Progress

Patient enrollment for ARTEMIS, the first P3 study for ixo-vec, is ahead of schedule.

Negative Factors

Delays in Study Initiation

The second P3 study, AQUARIUS, won't start until financing is secured.

Financial and Partnership Challenges

Given very limited cash and the need for a second pivotal P3 study for ixo-vec, a near-term announcement on meaningful financing or a significant partnership is critical.

Adverum Biotechnologies Business Overview & Revenue Model

Company Description

Adverum Biotechnologies, Inc. (ADVM) is a biotechnology company focused on discovering and developing gene therapy-based treatments for ocular and rare diseases. Utilizing its proprietary adeno-associated virus (AAV) technology platform, Adverum aims to develop novel therapies that can offer long-term efficacy and safety. The company's core product candidates are designed to address conditions with significant unmet medical needs, such as wet age-related macular degeneration and diabetic macular edema.

How the Company Makes Money

Adverum Biotechnologies generates revenue primarily through collaboration and licensing agreements with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestones, and royalties based on the successful development and commercialization of product candidates. Additionally, Adverum may receive funding from grants and research contracts to advance its gene therapy programs. The company's earnings are influenced significantly by the progress of its clinical trials and the potential market approval of its therapies.

Adverum Biotechnologies Financial Statement Overview

Summary

Adverum Biotechnologies is experiencing substantial financial challenges, with persistent operational losses reflected in its income statement. The balance sheet shows increasing leverage and a shrinking equity base, while cash flows remain strained with consistent operational cash outflows. The company needs to stabilize revenue streams and improve operational efficiencies to enhance financial health.

Income Statement

Adverum Biotechnologies has experienced significant challenges in its income statement. The company reported negative EBIT and net income for several years, indicating ongoing operational losses. The gross profit margin fluctuates with occasional positive figures, but the net profit margin remains negative, highlighting profitability issues. Revenue growth is erratic with periods of no revenue, showing instability in generating consistent revenue streams.

Balance Sheet

The balance sheet of Adverum Biotechnologies reveals a moderately leveraged position with a debt-to-equity ratio that suggests manageable debt levels relative to its equity. However, the company's equity has decreased over time, reflecting a reduction in financial stability. The equity ratio shows a decline, indicating that liabilities are becoming a larger portion of the company's financial structure, potentially increasing financial risk.

Cash Flow

Adverum Biotechnologies faces challenges in cash flow management. Operating cash flow has been consistently negative, which signifies operational struggles to generate cash. Free cash flow remains negative, indicating heavy cash outflows relative to inflows. Despite occasional financing inflows boosting cash reserves, the reliance on external financing could indicate potential liquidity risks without operational improvements.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-2.60M	1.00M	3.60M	0.00	7.50M	0.00
Gross Profit	-11.49M	-2.65M	-2.04M	-6.53M	2.85M	-4.16M
EBITDA	-83.89M	-127.27M	-123.30M	-147.93M	-140.90M	-112.23M
Net Income	-125.51M	-130.93M	-117.17M	-154.54M	-145.54M	-117.51M
Balance Sheet
Total Assets	137.65M	179.84M	173.01M	308.37M	439.73M	482.57M
Cash, Cash Equivalents and Short-Term Investments	83.08M	125.69M	96.53M	185.59M	305.19M	429.73M
Total Debt	93.18M	91.70M	75.04M	106.80M	102.99M	30.71M
Total Liabilities	111.23M	109.13M	89.54M	126.85M	123.54M	48.22M
Stockholders Equity	26.42M	70.71M	83.47M	181.52M	316.19M	434.35M
Cash Flow
Free Cash Flow	-112.51M	-92.85M	-91.71M	-119.91M	-122.95M	-91.14M
Operating Cash Flow	-111.99M	-92.46M	-90.90M	-108.09M	-107.83M	-79.29M
Investing Cash Flow	11.42M	-41.89M	96.88M	141.72M	78.71M	-280.17M
Financing Cash Flow	123.00K	120.00M	69.00K	607.00K	2.40M	355.99M

Adverum Biotechnologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADVM, the sentiment is Negative. The current price of 2.26 is below the 20-day moving average (MA) of 2.47, below the 50-day MA of 2.59, and below the 200-day MA of 4.82, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 43.45 is Neutral, neither overbought nor oversold. The STOCH value of 23.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADVM.

Adverum Biotechnologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.55B	0.30	-61.90%	2.27%	17.11%	1.58%
ADAG	49 Neutral	$87.15M	―	-55.14%	―	-99.43%	-69.40%
TCRX	48 Neutral	$80.92M	―	-78.93%	―	-70.15%	―
IGMS	42 Neutral	$79.35M	―	-245.59%	―	27.36%	23.82%
ADVM	40 Neutral	$47.63M	―	-127.99%	―	―	37.54%
ELTX	30 Underperform	$123.50M	―	-744.59%	―	―	27.65%

Adverum Biotechnologies Corporate Events

Adverum Biotechnologies Holds Annual Meeting with Key Votes

On June 17, 2025, Adverum Biotechnologies held its Annual Meeting, where stockholders voted on several key proposals. The election of Class II directors, ratification of Ernst & Young LLP as the independent accounting firm, and approval of executive compensation were among the decisions made. Additionally, stockholders approved amendments to the 2024 Equity Incentive Award Plan and the reduction of exercise prices for certain stock options, reflecting strategic adjustments to enhance shareholder value.

The most recent analyst rating on (ADVM) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Adverum Biotechnologies stock, see the ADVM Stock Forecast page.